GeoVax Labs, Inc. (NASDAQ:GOVX) Short Interest Up 341.9% in November

GeoVax Labs, Inc. (NASDAQ:GOVX) was the target of a large growth in short interest in November. As of November 15th, there was short interest totalling 1,330,000 shares, a growth of 341.9% from the October 31st total of 301,000 shares. Based on an average daily volume of 1,900,000 shares, the short-interest ratio is presently 0.7 days.

Analysts Set New Price Targets

A number of research firms have recently weighed in on GOVX. Alliance Global Partners began coverage on shares of GeoVax Labs in a research report on Monday, November 11th. They set a “buy” rating and a $15.00 target price for the company. D. Boral Capital reissued a “buy” rating and issued a $18.00 price target on shares of GeoVax Labs in a report on Tuesday, November 19th. Noble Financial lifted their target price on shares of GeoVax Labs from $6.00 to $10.00 and gave the company an “outperform” rating in a research note on Monday, August 19th. Finally, HC Wainwright reissued a “buy” rating and set a $8.00 price target on shares of GeoVax Labs in a research report on Friday, November 15th. Five investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, GeoVax Labs presently has an average rating of “Buy” and an average price target of $14.20.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in GeoVax Labs stock. Virtu Financial LLC purchased a new position in GeoVax Labs, Inc. (NASDAQ:GOVX) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 40,210 shares of the company’s stock, valued at approximately $97,000. Virtu Financial LLC owned 0.43% of GeoVax Labs as of its most recent SEC filing. Institutional investors and hedge funds own 6.09% of the company’s stock.

GeoVax Labs Stock Up 0.4 %

GeoVax Labs stock traded up $0.01 during trading hours on Thursday, hitting $2.71. The stock had a trading volume of 444,054 shares, compared to its average volume of 2,469,405. GeoVax Labs has a 12-month low of $1.09 and a 12-month high of $11.18. The stock’s 50-day moving average price is $2.34 and its 200-day moving average price is $2.68.

GeoVax Labs (NASDAQ:GOVX) last issued its earnings results on Tuesday, November 12th. The company reported ($0.91) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.29) by $0.38. The firm had revenue of $2.79 million during the quarter, compared to analysts’ expectations of $1.84 million. During the same period last year, the firm posted ($4.80) earnings per share. On average, analysts anticipate that GeoVax Labs will post -4.49 EPS for the current fiscal year.

About GeoVax Labs

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.